PCRX vs. SUPN, OPK, ALXO, ADCT, AVIR, NKTR, MCRB, CORT, ALKS, and PRGO
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Supernus Pharmaceuticals (SUPN), OPKO Health (OPK), ALX Oncology (ALXO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), Nektar Therapeutics (NKTR), Seres Therapeutics (MCRB), Corcept Therapeutics (CORT), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
99.7% of Pacira BioSciences shares are held by institutional investors. 6.6% of Pacira BioSciences shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Pacira BioSciences and Pacira BioSciences both had 3 articles in the media. Pacira BioSciences' average media sentiment score of 0.35 beat Supernus Pharmaceuticals' score of 0.30 indicating that Pacira BioSciences is being referred to more favorably in the media.
Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 6.22% compared to Supernus Pharmaceuticals' net margin of 0.22%. Pacira BioSciences' return on equity of 12.81% beat Supernus Pharmaceuticals' return on equity.
Pacira BioSciences has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.
Pacira BioSciences currently has a consensus target price of $49.50, suggesting a potential upside of 84.63%. Supernus Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 36.89%. Given Pacira BioSciences' higher probable upside, equities analysts clearly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
